Journal of Molecular Medicine

Journal of Molecular Medicine is a monthly peer-reviewed journal published by Springer that covers basic findings from disease pathogenesis to therapy across all human diseases, with a 2025 Journal Impact Factor of 5.0.《分子医学杂志》（Journal of Molecular Medicine）由（Springer）出版，月刊，覆盖从疾病发病机制到治疗的全部人类疾病基础研究，2025 年期刊影响因子为 5.0。

Scope

• The journal publishes original research articles and review articles that range from basic findings in the mechanisms of disease pathogenesis to therapy.刊物发表从疾病发病机制的基础发现到治疗应用的原创研究论文与综述。
• Its focus covers all human diseases, including aging, angiogenesis, autoimmune and other inflammatory diseases, cancer and cardiovascular diseases.其重点覆盖全部人类疾病，包括衰老、血管生成、自身免疫与其他炎症性疾病、癌症及心血管疾病。
• Development and differentiation, endocrinology, gastrointestinal disease and hepatology form further declared topics.发育与分化、内分泌学、胃肠疾病与肝病学构成其他明确列出的主题。
• Genetics and epigenetics, hematology, hypoxia research, immunology and infectious diseases are also in scope.遗传学与表观遗传学、血液学、缺氧研究、免疫学与感染性疾病同样在范围之内。
• Metabolic disorders and the neuroscience of disease complete the journal's thematic coverage.代谢性疾病与疾病神经科学补足了刊物的主题覆盖。
• Studies based on model organisms are considered if relevant to human disease, while studies based solely on cell lines are not considered.基于模式生物的研究在与人疾病相关时可被考虑，而仅基于细胞系的研究不予考虑。

History

• The journal continues the Berliner Klinische Wochenschrift, founded in 1864, where Paul Ehrlich, Robert Koch and Otto Warburg published early work.刊物承续 1864 年创办的《柏林临床周报》，保罗·埃利希、罗伯特·科赫与奥托·瓦尔堡都曾在该刊发表早期成果。
• It was previously published under the names Klinische Wochenschrift and The Clinical Investigator before adopting its present title.在采用现名之前，刊物曾以《临床周报》与《临床研究者》为刊名。
• Its history therefore runs from 1864 to the present, making it one of the longest-running molecular medicine titles.其历史自 1864 年延续至今，是分子医学领域历史最悠久的刊物之一。
• The journal is published by Springer in Germany and appears monthly.刊物由（Springer）在德国出版，按月发行。
• Its 2025 Journal Impact Factor is 5.0, after 4.2 in 2024 and 5.606 in 2022.2025 年期刊影响因子为 5.0，此前 2024 年为 4.2，2022 年为 5.606。
• Authors may publish either through the traditional route or by immediate gold open access, with no page charges for the former.作者可选择传统出版路径或即时金色开放获取，选择前者不需支付版面费。
• Colour artwork is provided free of charge in both print and online editions.印刷版与在线版的彩色图版均免费提供。

Editors

• The Editor-in-Chief is Ari Waisman, who leads the journal's editorial board.主编为（Ari Waisman），主持刊物编委会工作。
• Waisman works on neuroimmunology and inflammatory mechanisms, matching the journal's disease-mechanism orientation.（Waisman）从事神经免疫学与炎症机制研究，与刊物的疾病机制定位相契合。
• An international editorial board handles manuscripts across genetics, cell biology, biochemistry and translational medicine.国际化的编委会处理来自遗传学、细胞生物学、生物化学与转化医学方向的稿件。
• The journal screens out purely descriptive work and studies that rely only on established cell lines.刊物会筛除纯描述性工作以及仅依赖既有细胞系的研究。
• Manuscripts are submitted through the publisher's online system and peer reviewed, with an average review period of about six weeks.稿件经出版方在线系统提交并接受同行评审，平均审稿周期约六周。